Risk for Schizophrenia Increased With ED Visits Involving Hallucinogen Use
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 21, 2024 -- In individuals without a history of psychosis, the risk for developing a schizophrenia spectrum disorder (SSD) is increased for individuals with an emergency department visit involving hallucinogen use, according to a study published online Nov. 13 in JAMA Psychiatry.
Daniel T. Myran, M.D., M.P.H., from the University of Ottawa in Ontario, Canada, and colleagues conducted a population-based, retrospective cohort study involving all individuals aged 14 to 65 years in Ontario with no history of psychosis (SSD- or substance-induced) to examine whether an emergency department visit involving hallucinogen use is associated with an increased risk for developing an SSD. The study included 9,244,292 individuals without a history of psychosis who were followed for a median of 5.1 years.
The researchers found that 0.1 percent of the participants had an incident emergency department visit involving hallucinogen use. Between 2008 and 2012, the annual rates of incident emergency department visits involving hallucinogens were stable and then increased by 86.4 percent between 2013 and 2021 from 3.4 to 6.4 per 100,000 individuals. Compared with the general population, individuals with emergency department visits involving hallucinogens had a greater risk for being diagnosed with an SSD within three years (absolute proportion with SSD at three years: 3.99 versus 0.15 percent; age- and sex-adjusted hazard ratio, 21.32). The increased risk persisted after adjustment for comorbid substance use and mental health conditions (hazard ratio, 3.53). In the fully adjusted model, compared with emergency department visits involving alcohol and cannabis, emergency department visits involving hallucinogens were associated with an increased risk for SSD within three years.
"Given rapid increases in interest in and adult use of hallucinogens and the increase in emergency department visits involving hallucinogens found in this study, ongoing research is needed to clarify the observed association between hallucinogen use and development of SSD," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Chronic Exposure to Systemic Inflammation May Increase Risk for Affective Disorders
THURSDAY, July 3, 2025 -- For individuals with specific autoimmune conditions, there appears to be an increased risk for affective disorders, according to a study published online...
Weekly LYN-005 Provides Sustained Risperidone Release in Schizophrenia
WEDNESDAY, June 18, 2025 -- For patients with schizophrenia, weekly LYN-005 provides sustained release of risperidone at therapeutic concentrations, according to a study published...
Better Adherence to Antipsychotics Linked to Lower Vehicle Crash Risk
MONDAY, June 9, 2025 -- For drivers with schizophrenia, better adherence to antipsychotic medications is associated with lower motor vehicle crash risk, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.